Anzeige
Mehr »
Mittwoch, 08.10.2025 - Börsentäglich über 12.000 News
Defence-Aktie mit Ritterschlag: Regierungs-Einladung zur größten Militärmesse
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EFZT | ISIN: SE0020181014 | Ticker-Symbol: MVR0
Stuttgart
08.10.25 | 07:45
0,119 Euro
+6,83 % +0,008
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MEDIVIR AB Chart 1 Jahr
5-Tage-Chart
MEDIVIR AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,0530,07012:56

Aktuelle News zur MEDIVIR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MEDIVIR Aktie jetzt für 0€ handeln
08:55Medivir AB: Medivir announces a fully guaranteed rights issue of approximately SEK 151 million47THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA...
► Artikel lesen
21.08.Medivir AB: Interim Report January - June 202598"Fostrox + Lenvima has great potential to take the place as the first approved drug treatment in second-line liver cancer" April - JuneFinancial summary for the quarterNet turnover amounted to SEK 1.5...
► Artikel lesen
29.04.Medivir AB: Interim Report January - March 2025207"Final data from phase 2a study underscores potential for fostrox + Lenvima to become first approved option in second-line liver cancer" January - MarchFinancial summary for the quarterNet turnover...
► Artikel lesen
19.03.Medivir AB: Medivir receives European patent for fostrox plus lenvatinib in treatment of hepatocellular carcinoma (HCC) and cancer metastases in the liver182Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces today that the...
► Artikel lesen
25.02.Medivir AB: Medivir's partner Infex Therapeutics signs a license agreement for the clinical development of MET-X in India185Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces today that its...
► Artikel lesen
18.02.Medivir AB: Year-End Report January - December 2024316"We are now, within short, ready to initiate the phase 2b study - with the goal of making fostrox + Lenvima the first approved medical treatment for second-line liver cancer" October - DecemberFinancial...
► Artikel lesen
06.11.24Medivir AB: Interim Report January - September 202495"The improved results presented at ESMO and the collaboration agreement with Eisai have strengthened fostrox's chances of becoming the first approved therapy in second-line liver cancer". July - SeptemberFinancial...
► Artikel lesen
7 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1